Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Open access
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., LeBoeuf, N. R., Lenihan, D., Onofrei, C., Shannon, V., Sharma, R., Silk, A. W., Skondra, D., Suarez-Almazor, M. E., Wang, Y., Wiley, K., Kaufman, H. L., Ernstoff, M. S. · 2017 · Journal for ImmunoTherapy of Cancer

Abstract

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. Immunotherapy-related irAEs typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. There is an urgent need for multidisciplinary guidance reflecting broad-based perspectives on how to recognize, report and manage organ-specific toxicities until evidence-based data are available to inform clinical decision-making. The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here we present their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-017-0300-z

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Distribution of mild and severe immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy. [Adapted from [88]]
Fig. 1 Distribution of mild and severe immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy. [Adapted from [88]]CC BY · PubMed Central
Fig. 2 Pharmacokinetic/pharmacodynamic differences between chemotherapy and immunotherapy. Reproduced with permission from [25]. Dotted blue line represents waning of the biological effects of immunotherapy over time, and solid blue line represents early or late toxic effects. Horizontal dotted blue arrow therefore represents duration of immunotherapy treatment benefit
Fig. 2 Pharmacokinetic/pharmacodynamic differences between chemotherapy and immunotherapy. Reproduced with permission from [25]. Dotted blue line represents waning of the biological effects of immunotherapy over time, and solid blue line represents early or late toxic effects. Horizontal dotted blue arrow therefore represents duration of immunotherapy treatment benefitCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 97 references

Research works printed but not linked: 1

  1. Marie Joelle Pitteloud RD, Cabanillas ME, Shah K, Mimi I-Nan H, Habra MA, Waguespack SG, et al. Hypophysitis in the Age of Cancer Immunotherapy: Experience in a Large Cancer Center, in Endocrine Society’s 97th Annual Meeting and Expo. San Diego: CA; 2015.

Cited by

See all 1,992

Metadata

Authors
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., LeBoeuf, N. R., Lenihan, D., Onofrei, C., Shannon, V., Sharma, R., Silk, A. W., Skondra, D., Suarez-Almazor, M. E., Wang, Y., Wiley, K., Kaufman, H. L., & Ernstoff, M. S.
Affiliations
  • Roswell Park Comprehensive Cancer Center (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Johns Hopkins University (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Washington University in St. Louis (US)
  • University of Chicago (US)
  • Oncology Nursing Society (US)
Corresponding author
Ernstoff, M. S.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2017-11-21
Volume
5
Issue
1
Pages
95-95
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2768429453
Cited by
1,992
References
97
Citations by year
2026: 125 · 2025: 158 · 2024: 204 · 2023: 235 · 2022: 258 · 2021: 328 · 2020: 344 · 2019: 229 · 2018: 109
FWCI
82.20
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The Medicine Forum (submittedVersion, public-domain)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • Bristol-Myers Squibb
  • AstraZeneca
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
immune checkpoint inhibitors, immune-related adverse events, irAE management, toxicity management, consensus recommendations, skin toxicity, endocrine toxicity, pulmonary toxicity, musculoskeletal toxicity, immunosuppression, immunomodulatory therapy
MeSH terms
Clinical Decision-Making, Humans, Immunotherapy, Neoplasms, Societies, Medical, Practice Guidelines as Topic, Evidence-Based Medicine, Neurotoxicity Syndromes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. https://app.cochat.ai/papers/10.1186/s40425-017-0300-z
The paper
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., LeBoeuf, N. R., Lenihan, D., Onofrei, C., Shannon, V., Sharma, R., Silk, A. W., Skondra, D., Suarez-Almazor, M. E., Wang, Y., . . . Ernstoff, M. S. (2017). Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-017-0300-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.